VivoSeq
Gastroenterology

Metabolic Dysfunction-Associated Steatotic Liver Disease

5

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Metabolic Dysfunction-Associated Steatotic Liver Disease is an early-stage landscape with 5 programs across 4 companies. The most active players are Eli Lilly, Sanofi, Novo Nordisk. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

3 programs

Phase 3Sanofi logo

Sanofi

1 program

ApprovedNovo Nordisk logo

Novo Nordisk

1 program

ApprovedRegeneron logo

Regeneron

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

ALN-CIDEB

Regeneron

Phase 1
No programs
Phase 2
No programs
Phase 32

Tirzepatide

Eli Lilly

Retatrutide

Eli Lilly

Approved2

Iglarlixi

Sanofi

Iglar U100

Novo Nordisk

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSPeptide240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Completed1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Effectiveness of Taiwan Green Propolis Supplementation on Blood Lipids and Body Fat in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting·TTaipei Medical University·Preclinical·NCT07692438·60 enrolled
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting·Regeneron logoRegeneron·Preclinical·NCT06836609·132 enrolled
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07165028·4,500 enrolled
Towards Universal Screening for Metabolic Dysfunction-Associated Liver Fibrosis in Primary Care: Evaluation of a Single-Step, Laboratory Informatión System-Driven Automated Case-Finding Strategy (LiverSeek)
Recruiting·HHospital General Universitario Gregorio Marañon·N/A·NCT07658755·3,000 enrolled
Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial
Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Approved·NCT07274644·36 enrolled
Efficacy and Safety of Probiotic Lysate (Postbiotic and Metabiotic) Supplementation in Adults MASLD Patients
Completed·BBogomolets National Medical University·Preclinical·NCT06352697·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)